SecBot SecBot
SECBOTREPLAY Home › Report › RCKT

RCKT · Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease…

ROCKET PHARMACEUTICALS, INC. · 8-K filed Jun 12, 2026 at 07:10 ET

At the news

BULLISHIMPACT 5/10

8-K filed Jun 12, 2026 at 07:10 ET

Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million in gross proceeds, a previously announced transaction. The non-dilutive capital infusion boosts pro-forma cash to approximately $322.6 million and extends the company's cash runway into the second quarter of 2028, strengthening its balance sheet as it advances its cardiovascular gene therapy pipeline.

  • Completed sale of PRV for $180.0 million in gross proceeds
  • Pro-forma cash, cash equivalents and investments increased to approximately $322.6 million
  • Cash runway extended into Q2 2028
  • Transaction closed on June 10, 2026, announced via press release on June 12, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access